Postoperative ctDNA (molecular residual disease, MRD) is emerging as a strong prognostic tool in colorectal cancer, but most rectal cancer data come from cohorts exposed to neoadjuvant therapy/TNT, which complicates…
GALAXY Study: Postoperative ctDNA as a Prognostic and Predictive Biomarker in Stage II–III Rectal Cancer
